- Home
- GRVY vs DCTH Comparison
GRVY vs DCTH Comparison
Compare GRVY & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRVY
- DCTH
- Stock Information
- Founded
- GRVY 2000
- DCTH 1988
- Country
- GRVY South Korea
- DCTH United States
- Employees
- GRVY N/A
- DCTH N/A
- Industry
- GRVY Business Services
- DCTH Medical/Dental Instruments
- Sector
- GRVY Consumer Discretionary
- DCTH Health Care
- Exchange
- GRVY Nasdaq
- DCTH Nasdaq
- Market Cap
- GRVY 446.3M
- DCTH 388.3M
- IPO Year
- GRVY 2005
- DCTH N/A
- Fundamental
- Price
- GRVY $59.50
- DCTH $10.26
- Analyst Decision
- GRVY
- DCTH Strong Buy
- Analyst Count
- GRVY 0
- DCTH 4
- Target Price
- GRVY N/A
- DCTH $24.25
- AVG Volume (30 Days)
- GRVY 18.2K
- DCTH 1.0M
- Earning Date
- GRVY 11-11-2025
- DCTH 11-04-2025
- Dividend Yield
- GRVY N/A
- DCTH N/A
- EPS Growth
- GRVY N/A
- DCTH N/A
- EPS
- GRVY 8.59
- DCTH 0.06
- Revenue
- GRVY $404,804,469.00
- DCTH $70,240,000.00
- Revenue This Year
- GRVY N/A
- DCTH $146.50
- Revenue Next Year
- GRVY N/A
- DCTH $37.19
- P/E Ratio
- GRVY $6.93
- DCTH $182.85
- Revenue Growth
- GRVY N/A
- DCTH 491.35
- 52 Week Low
- GRVY $53.12
- DCTH $8.87
- 52 Week High
- GRVY $70.00
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- GRVY 42.12
- DCTH 40.56
- Support Level
- GRVY $57.69
- DCTH $10.05
- Resistance Level
- GRVY $58.97
- DCTH $12.70
- Average True Range (ATR)
- GRVY 1.47
- DCTH 0.70
- MACD
- GRVY 0.01
- DCTH -0.13
- Stochastic Oscillator
- GRVY 60.35
- DCTH 7.74
About GRVY GRAVITY Co. Ltd. American Depository Shares
GRAVITY Co Ltd is an online and mobile games developer and publisher based in Korea. Its principal product, Ragnarok Online, is an online game which is available in more than 91 markets. Its games include Ragnarok Online, Requiem, Dragonica (Dragon Saga), Ragnarok Online II, Requiem Online, and R.O.S.E. Online. The company generates revenue from online games, mobile games and other sources including character based merchandise and animation.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.